Catecholaminergic Contributions to Inhibitory Control Following Physical Fatigue: Behavioral and Neurophysiological Findings

Acute physical fatigue can impair cognitive control, yet its underlying neurochemical mechanisms remain unclear. This study investigated whether catecholaminergic modulation influences behavioral and neural markers of inhibitory control following physical fatigue. Eighteen healthy, recreationally active adults (9 males, 9 females; 23.4 ± 2.2 years) completed a randomized, triple‐blind, placebo‐controlled crossover study. On separate visits, participants received methylphenidate (MPH; 20 mg; a dopamine and noradrenaline reuptake inhibitor), reboxetine (REB; 8 mg; a noradrenaline reuptake inhibitor), or placebo. Physical fatigue was induced by repeated bilateral leg extensions to task failure. Cognitive performance was assessed before and after physical fatigue using a Go/No‐Go task with electroencephalographic recording. Behavioral outcomes included reaction time and accuracy, while event‐related potentials measured neural stages of response execution and inhibition (N2 and P3). Mixed‐effects models were used for statistical analysis. For No‐Go trials, a significant MPH × Time interaction was observed for accuracy ( p  = 0.008), with improved post‐fatigue performance following MPH administration ( p  = 0.048). At the neural level, MPH was associated with shorter fronto‐central No‐Go N2 latency ( p  = 0.038) and altered fatigue‐related changes in No‐Go P3 latency ( p  = 0.047). REB did not produce comparable behavioral or neural effects. These findings provide pharmacological evidence that catecholaminergic mechanisms contribute to inhibitory control following physical fatigue. The differential effects of MPH and REB suggest that selective noradrenergic enhancement alone is insufficient to maintain inhibitory control following physical fatigue. Instead, the findings implicate broader dopaminergic and noradrenergic mechanisms, potentially involving alterations in the temporal dynamics of inhibitory processing.

Trial Registration

(G095422N and identifier NCT05880342)